WO2006066863A1 - Asymmetric hydrogenation of alkennes using chiral iridium complexes - Google Patents
Asymmetric hydrogenation of alkennes using chiral iridium complexes Download PDFInfo
- Publication number
- WO2006066863A1 WO2006066863A1 PCT/EP2005/013694 EP2005013694W WO2006066863A1 WO 2006066863 A1 WO2006066863 A1 WO 2006066863A1 EP 2005013694 W EP2005013694 W EP 2005013694W WO 2006066863 A1 WO2006066863 A1 WO 2006066863A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- process according
- phenyl
- chiral
- complex
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/70—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with two hydrocarbon radicals attached in position 2 and elements other than carbon and hydrogen in position 6
- C07D311/72—3,4-Dihydro derivatives having in position 2 at least one methyl radical and in position 6 one oxygen atom, e.g. tocopherols
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B53/00—Asymmetric syntheses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
- C07C29/17—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by hydrogenation of carbon-to-carbon double or triple bonds
- C07C29/172—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by hydrogenation of carbon-to-carbon double or triple bonds with the obtention of a fully saturated alcohol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/27—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation
- C07C45/30—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation with halogen containing compounds, e.g. hypohalogenation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/62—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by hydrogenation of carbon-to-carbon double or triple bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
- C07C67/303—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by hydrogenation of unsaturated carbon-to-carbon bonds
Definitions
- the present invention relates to the (stereoselective) hydrogenation of a compound of the formula II with at least one carbon-carbon double bond, especially to the (stereoselective) hydrogenation of isoprenoids, non-cyclic sesquiterpenes, tocomonoenols, tocodienols, tocotrienols or any derivatives thereof, as well as to the (stereoselective) hydrogenation of parts/extracts of plant oils containing such tocotrienols or derivatives thereof, in the presence of a chiral Ir complex as the catalyst, whereby preferably one stereoisomer is manufactured in an excess.
- one aspect of the invention refers to a process for the manufacture of at least one compound of the formula I
- R 2 being a hydroxyl group or a protected hydroxyl group
- R 3 and R 4 being independently from each other hydrogen or methyl
- n being an integer from 1 to 10, preferably from 1 to 3
- a chiral Ir complex as the catalyst.
- one stereoisomer of the compound I is manufactured in excess.
- a compound of formula II with only one prochiral center is used preferably one enantiomer is manufactured in excess.
- the stereoselectivity of the hydrogenation can be controlled by appropriate choive of the catalyst.
- Hal (E)-Dihydrogeranylacetone
- Ha2 (Z)-dihydronerylacetone
- Ha3 (E)- geranylacetone
- IIa4 (Z)-nerylacetone
- Kb (all-E)-farnesol
- lie (all-E)-farnesene acid ethyl ester
- S)-XII (2S,3'E,7'E)-tocotrienol and derivatives thereof
- R)-XII
- the compound of the formula II is an isoprenoid, a non-cyclic sesquiterpene, a tocomonoenol, a tocodienol or a tocotrienol.
- An isoprenoid is an oligo(isoprene) or a poly(isoprene) and derivatives thereof which contain at least one carbon-carbon double bond.
- the carbon-carbon double bond has the E configuration.
- the tocomonoenol, the tocodienol and/or the tocotrienol is of the formula XIII,
- R 2 is a hydroxyl group or a protected hydroxyl group and R 3 and R 4 are independently from each other hydrogen or methyl.
- Compound XHI thus encompasses (3 'E)-tocomonoenols, (7 ⁇ )-tocomonoenols, (H')- tocomonoenols, (3'E,7'E)-tocodienols, (3 ⁇ ,ll')-tocodienols, (7'E,ll>tocodienols, as well as (3 ⁇ ,7'E)-tocotrienols.
- R 2 is a hydroxyl group or a protected hydroxyl group.
- the hydroxyl group can be protected as ether, ester, or acetal.
- ethers and acetals are the methylether, the methoxymethylether, the mmeetthhooxxyyeetthhyylleetthheerr aanndd tthhee tteettrraahhyyddrrcopyranyl ether, as well as compounds where R 2 is ethoxyethyl or methoxyethoxyethyl.
- esters are the acetic acid ester and esters with other carbonic acids such as formic acid ester, succinic acid monoester (or derivatives), propionic acid ester, benzoic acid ester and palmitic acid ester.
- R 2 is a protected hydroxyl group, whereby the hydroxyl group is protected as ether or ester, more preferably as ester, especially preferably R 2 is acetyloxy.
- the present invention is also concerned with a process for the manufacture of a hydrogenated part or extract of a plant oil, preferably of palm oil, comprising the step of hydrogenating the part or extract of the plant oil comprising at least a tocotrienol or derivative thereof in the presence of a chiral Lr complex as the catalyst. That means in the present invention such "a part or extract of the plant oil comprising at least a tocotrienol or derivative thereof is also encompassed by the term "compound of the formula II with at least one carbon-carbon double bond".
- part of a plant oil encompasses any untreated or treated part of the plant oil, any concentrated part as well as the whole plant oil itself, "treated” means chemically treated such as distilled or extracted or thermally treated.
- the edible plant oil is treated in such a way that a part is obtained where the tocotrienols originally contained in the edible plant oil are enriched ("concentrate"). This part of the edible plant oil can be per se not edible.
- plant oils are any edible plant oils known to the person skilled in the art. Especially preferred is palm oil which contains beside small amounts of ⁇ - and ⁇ - tocopherol large amounts of tocotrienols.
- the tocotrienol or the derivative thereof is hydrogenated to a tocopherol (derivative), preferably to a highly stereoisomerically enriched (all-R)-tocopherol (derivative).
- Suitable catalyst for the process of the present invention are Ir complexes with chiral organic ligands, especially those disclosed by A. Pfaltz et al. in Adv. Synth. Catal. 2003, 345 (1 + 2), 33-43; by F. Menges and A. Pfaltz in Adv. Synth. Catal. 2002, 344 (1), 40- 44;by J. Blankenstein and A. Pfaltz in Angew. Chem. Int. Ed. 2001, 40 (23), 4445-4447, by A. Pfaltz in Chimia 2004, 58 (1 + 2), 49-50 and in US 6,632,954.
- Suitable catalysts are especially the Lr complexes of the formula HI, IV, V, VI, VII, VIE, IX, X , XI or XV and their enantiomers
- R, X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , X 8 , X 9 , X 10 , X n , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , X 18 , X 19 ,X 20 ,X 21 and X 22 are independently from each other hydrogen, C 1-4 -alkyl, C 5-7 - cycloalkyl, phenyl (optionally substituted with one to three Ci-4-alkyl, Q-4-alkoxy and/or C ⁇ - perfluoroalkyl groups), benzyl, 1-naphthyl, or ferrocenyl,
- the anion Y is a low coordinating anion, n is 1 or 2, and
- o-Tol means ortho-tolyl
- Ph means phenyl
- TDMS means tert-butyl-di- methylsilyl
- p-Tol means para-tolyl
- BA ⁇ F means tetra(3,5-bis(triJfluoromethyl)- phenyl)borate.
- Suitable catalysts are also the corresponding Ir complexes and their enatiomers, in which the cyclooctadiene ligand is replaced by olefins, e.g. ethene, norbornadiene.
- Preferred chiral Ir complexes suitable for the process of the present invention are Ir complexes of the formulae IE to XI, wherein
- X 21 and X 22 are independently from each other hydrogen, C 1-4 -alkyl, C 5-7 -cycloalkyl, phenyl (optionally substituted with one to three d- 4 -alkyl, C 1-4 -alkoxy and/or C 1-4 - perfluoroalkyl groups), benzyl, 1-naphthyl, or ferrocenyl, and
- the anion Y is a weakly coordinating anion such as PF 6 " , SbF 6 " , BAT F “ , BF 4 " , F 3 C-SO 3 " , ClO 4 " , tetra(perfluoroaryl)borate or tetra(perfluoroalkyloxy)aluminate whereby the perfluoroaryl is a phenyl substituted with 1 to 5 perfluoro-C 1-4 -alkyl groups and the per- fluoroalkyloxy has 1 to 4 carbon atoms.
- Ir complexes of the formulae III to XI and XV wherein
- X 21 and X 22 are independently from each other hydrogen, methyl, ethyl, iso-propyl, n- butyl, iso-butyl, tert-butyl, cyclohexyl, phenyl, benzyl, o-tolyl, m-tolyl, 4-methoxyphenyl, 4-trifluoromethylphenyl, 3,5-di-tert-butylphenyl, 3,5-dimethoxyphenyl, 1-naphthyl, or ferrocenyl, and
- the anion Y is tetra(perfiuoroaryl)borate or tetra(perfluoroalkyloxy)aluminate whereby the perfluoroaryl is a phenyl substituted with 1 to 3 perfluoro-Ci -4 -alkyl groups and the per- fluoroalkyloxy has 1 to 4 carbon atoms.
- More preferred chiral Ir complexes suitable for the process of the present invention are Lr complexes of the formulae IH to XI, and XV, wherein R, X 5 , X 14 and X 20 , X 21 , and X 22 are independently from each other hydrogen, iso-propyl, tert-butyl, phenyl, 3,5-di-tert-butylphenyl or ferrocenyl,
- X 1 and X 2 are independently from each other phenyl, o-tolyl, cyclohexyl or iso-propyl, preferably X 1 and X 2 as well as X 7 and X 8 or X 9 and X 10 or X 15 and X 16 are the same,
- X 3 and X4 as well as X 11 and X 12 as well as X 17 and X 18 are independently from each other methyl, ethyl, n-butyl, iso-butyl or benzyl, preferably X 3 and X 4 , X 11 and X 12 , X 17 and X 18 are the same,
- X 6 is hydrogen or methyl
- X 13 and X 19 are independently from each other phenyl, cyclohexyl, 4-methoxyphenyl, 3,5- dimethoxyphenyl, 4-trifluoromethylphenyl, benzyl, m-tolyl or 1-naphthyl,
- Y is tetra(3,5-bis(trifluoromethyl) ⁇ henyl)borate [B(3,5-C 6 H 3 (CF 3 ) 2 ) 4 ] ⁇ or tetra(perfluorotert-butyloxy)aluminate [A1(OC(CF 3 ) 3 ) 4 ] ⁇ and n is as defined earlier.
- R is hydrogen, iso-propyl or tert-butyl
- X 1 and X 2 are independently from each other phenyl, o-tolyl, cyclohexyl or iso-propyl, preferably X 1 and X 2 are the same,
- X 3 and X 4 are independently from each other benzyl or iso-butyl, preferably X 3 and X 4 are the same,
- X 5 is phenyl, 3,5-di-tert-butylphenyl or ferrocenyl,
- X 6 is hydrogen or methyl
- X 7 and X 8 are independently from each other phenyl or cyclohexyl, preferably X 7 and X 8 are the same,
- X 9 and X 10 are independently from each other phenyl or o-tolyl, preferably X 9 and X 10 are the same, X 1 ' and X 12 are independently from each other methyl, ethyl or n-butyl, preferably X 1 and X are the same,
- X 13 is phenyl, cyclohexyl, 4-methoxyphenyl, 3,5-dimethoxyphenyl, 4- trifluoromethylphenyl, benzyl, m-tolyl or 1-naphthyl,
- X !4 is iso-propyl or tert-butyl
- X 15 and X 16 are independently from each other phenyl or o-tolyl, preferably X 15 and X 16 are the same,
- X 17 and X 18 are independently from each other methyl or n-butyl, preferably X 17 and X 18 are the same,
- X 19 is phenyl or 1-naphthyl
- X is iso-propyl or tert-butyl
- Y is tetra(3,5-bis(trifluoromethyl) ⁇ henyl)borate [B(3,5-C 6 H 3 (CF 3 ) 2 ) 4 ] ⁇ or tetraperfluorotert-butyloxyaluminate [A1(OC(CF 3 ) 3 ) 4 ] ⁇ and n is as defined earlier.
- the most preferred chiral Ir complexes suitable for the process of the present invention are the Ir complexes of the formulae HI to XI presented in the Fig. 1 to 3.
- the following abbreviations are used in the formulae:
- Cy cyclohexyl
- Bn benzyl
- i-Bu iso-butyl
- n-Bu n-butyl
- t-Bu tert- butyl
- Fc ferrocenyl
- o-Tol o-tolyl
- p-Tol p-tolyl
- i-Pr iso-propyl
- Me methyl
- Ph phenyl
- TDMS tert-butyl-dimethyl silyl
- BAr F is tetra(3,5- bis(trifluoromethyl)phenyl)borate [B(3,5-C 6 H 3 (CF 3 ) 2 ) 4 ] ⁇ .
- Fig. 1 shows preferred Ir complexes of the formula IQ (Al, A2, A4, A5, Gl) and IV (Cl, C2, C5, C6).
- Fig. 2 shows preferred Ir complexes of the formulae VII (El and E3 to E14).
- Fig. 3 shows the Ir complexes of the formulae V (Bl), VI (Dl), VIE (E2, E15), IX (Fl), X (C4), XI (B2) and XV (Hl). Reaction conditions
- the amount of the catalyst is conveniently from about 0.05 to about 5 mol %, preferably from about 0.09 to about 2.5 mol %, more preferably from about 0.1 to about 2.0 mol-%, based on the amount of the compound of the formula II.
- halogenated aliphatic hydrocarbons are mono- or polyhalogenated linear, branched or cyclic C 1 - to Qs-alkanes. Especially preferred examples are mono- or polychlorinated or -brominated linear, branched or cyclic C 1 - to Cis-alkanes. More preferred are mono- or polychlorinated linear, branched or cyclic C 1 - to Ci 5 -alkanes. Mostpreferred are dichloromethane, 1,2-dichloroethane, toluene 1,1,1-trichloroethane, chloroform, and methylene bromide. Further, toluene, benzene, and chlorobenzene come into consideration.
- the reaction may be carried out under solvent free conditions, or in presence of one or more of the solvents mentioned above.
- concentration of the reactants in the solution is not critical.
- the reaction is conveniently carried out at an absolute pressure of hydrogen from about 1 to about 100 bar, preferably at an absolute pressure of hydrogen from about 20 to about 75 bar.
- the reaction temperature is conveniently between about 0 to about 100°C, preferably between about 10 to about 4O 0 C.
- the sequence of addition of the reactants and solvent is not critical.
- (Z)-nerylacetone or (E)- geranylacetone or any mixture thereof is hydrogenated in the presence of a chiral Ir complex selected from the group consisting of catalyst A2 (see Fig. 1), Dl (see Fig. 3), Bl (see Fig. 3) and El (see Fig.
- the hydrogenation is stereoselective in that way that one enantiomer is present in the mixture in an enantiomeric excess, preferably of at least 84%, more preferably of at least 90%.
- E-farnesol is hydrogenated in the presence of the chiral Ir complex El (see Fig. 2) or Bl (see Fig. 3) to form a mixture of two enantiomeric pairs (3R,7S)-3,7,11-trimethyldodecane-l-ol and (3S,7R)-3,7,11- trimethyldodecane-1-ol as well as (3R,7R)-3,7,11-trimethyldodecane-l-ol and (3S,7S)- 3,7,11-trimethyldodecane-l-ol.
- the stereoisomer (3S,7S)-3,7,11- trimethyldodecane-1-ol is present in the mixture obtained after the hydro genation in an excess compared to the other stereoisomers, preferably in an amount of at least 70%, more preferably in an amount of at least 75%.
- (E)-farnesene acid ethyl ester is hydrogenated in the presence of the chiral Ir complex Bl (see Fig. 3) or El (see Fig. 2) to form a mixture of two enantiomeric pairs (3R,7S)-3,7,ll-trimethyldodecanoic acid ethyl ester and (3S,7R)-3,7,11- trimethyldodecanoic acid ethyl ester as well as (3R,7R)-3,7,11- trimethyldodecanoic acid ethyl ester and (3S,7S)-3,7,11- trimethyldodecanoic acid ethyl ester.
- the hydro genation is preferably stereoselective in that way that the stereoisomer (3S,7S)-3,7,11- trimethyldodecanoic acid ethyl ester is manufactured - compared to the other stereoisomers - in an excess, preferably in an amount of at least 55%, more preferably in an amount of at least 70%.
- (2R,3'E,7'E)- ⁇ -tocotrienyl acetate is hydrogenated in the presence of the chiral Ir complex El (see Fig. 2), E2 (see Fig. 3), E7 (see Fig. 2)or E15 (see Fig.
- the stereoisomer (2R,4'R,8'R)- ⁇ -tocopheryl acetate - compared to the other diastereoisomers - is manufactured in an excess, preferably in an amount of at least 55%, more preferably in an amount of at least 90%.
- (2S,3'E,7 ⁇ )- ⁇ -tocotrienyl acetate is hydrogenated in the presence of a chiral Ir complex selected from the group consisting of E3, E4, E6, E8, E9, ElO, El l, E12, E13, E14 (all Fig.
- the diastereoisomer (2S,4'S,8 'S)- ⁇ -tocopheryl acetate is manufactured in an excess - compared to the other diastereoisomers, preferably in an amount of at least 65%, more preferably in an amount of at least 85%.
- (2R,3 ⁇ ,7'E)- ⁇ -tocotrienyl acetate is hydrogenated in the presence of the chiral Ir complex Cl (see Fig. 1), Dl (see Fig. 3), El (see Fig. 2) or Fl (see Fig.
- the diastereoisomer (2R,4'R,8'R)- ⁇ -tocopheryl acetate is manufactured in an excess - compared to the other diastereoisomers, preferably in an amount of at least 45%.
- catalysts for use in the present invention are the chiral complexes represented by the formulae El to E 15.
- the present invention is also directed to the use of a chiral Ir complex, especially one of the formulae EI to XI as described above, as catalyst for the (stereoselective) hydrogenation of a compound selected from the group consisting of isoprenoids, non- cyclic sesquiterpenes, tocomonoenols, tocodienols and tocotrienols.
- Fig. 1 shows preferred Ir complexes of the formula m (Al, A2, A4, A5, Gl) and IV (Cl, C2, C5, C6).
- Fig. 2 shows preferred Ir complexes of the formulae VII (El and E3 to E 14).
- Fig. 3 shows the Ir complexes of the formulae V (Bl), VI (Dl), VHI (E2, E15), IX (Fl) 5 X (C4) and XI (B2).
- TLC thin layer chromatography
- GC gas chromatography
- GC-MS gas chromatography - mass spectrometry
- HPLC high pressure/performance liquid chromatography
- the GC analyses were performed with an Agilent 6890 GC FID on a CP-Sil-88 (Chrompack, Netherlands) 50m x 0.25mm column.
- the carrier gas was hydrogen with 90 kPa.
- the samples were injected as 0.3% solutions in dichloromethane with a split ratio of 1/30.
- the injector was held at 250°C whereas the oven temperature was programmed from 110-200°C at 0.5°C/min, the detector was at 250°C.
- the hydrogenation was carried out according to procedure 1, whereby 0.25 mmol of the substrate and 1 mol-% of the Ir-catalyst were used.
- the following substrates were used:
- Examples 34 to 39 Preparation of 3,7,11-trimethyl-dodecanoic acid ethyl ester
- the isolated alcohol e.g., 3 ,7, 11 -trimethyldodecan- 1 -ol was further reacted to the corresponding aldehyd, e.g., 3 ,7 J 1 -trimethyl-dodecanal without any purification.
- Examples 62 to 68 f2iO- ⁇ -tocopheryl acetate and ⁇ - ⁇ -tocopheryl acetate
- tocopheryl acetates were converted into tocopherols and tocopherol methyl ethers as follows:
- the aqueous phase was extracted with 10 ml of n-hexane.
- the combined organic phases were dried over MgSO 4 and the solvent evaporated.
- the obtained raw product was analyzed without any further purification via GC to determine the ratio of the diastereomers.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Pyrane Compounds (AREA)
- Catalysts (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007547315A JP5090926B2 (en) | 2004-12-22 | 2005-12-20 | Asymmetric hydrogenation of alkenes using chiral iridium complexes |
CN2005800445184A CN101087774B (en) | 2004-12-22 | 2005-12-20 | Asymmetric hydrogenation of alkenes using chiral iridium complexes |
AT05820633T ATE520678T1 (en) | 2004-12-22 | 2005-12-20 | ASYMMETRIC HYDROGENATION OF ALKENES WITH CHIRAL IRIDIUM COMPLEX |
US11/793,729 US8426617B2 (en) | 2004-12-22 | 2005-12-20 | Asymmetric hydrogenation of alkenes using chiral iridium complexes |
EP20050820633 EP1828159B1 (en) | 2004-12-22 | 2005-12-20 | Asymmetric hydrogenation of alkenes using chiral iridium complexes |
KR1020077016839A KR101342722B1 (en) | 2004-12-22 | 2007-07-20 | Asymmetric Hydrogenation of Alkenes Using Chiral Iridium Complexes |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04030432.1 | 2004-12-22 | ||
EP04030432 | 2004-12-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006066863A1 true WO2006066863A1 (en) | 2006-06-29 |
Family
ID=35994658
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2005/013694 WO2006066863A1 (en) | 2004-12-22 | 2005-12-20 | Asymmetric hydrogenation of alkennes using chiral iridium complexes |
Country Status (8)
Country | Link |
---|---|
US (1) | US8426617B2 (en) |
EP (1) | EP1828159B1 (en) |
JP (1) | JP5090926B2 (en) |
KR (1) | KR101342722B1 (en) |
CN (1) | CN101087774B (en) |
AT (1) | ATE520678T1 (en) |
ES (1) | ES2371653T3 (en) |
WO (1) | WO2006066863A1 (en) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2466629A (en) * | 2008-12-29 | 2010-06-30 | Schlumberger Holdings | Catalytic hydrogenation at a double bond with a transition metal complex of a heterocyclic nitrogenous organic base comprising a cyclic amidine group |
WO2010125035A1 (en) * | 2009-04-30 | 2010-11-04 | Basf Se | Metal complex with low-coordinating counterion as polymerization catalyst for isobutes or an isobute-containing monomer composition |
WO2012025502A1 (en) | 2010-08-23 | 2012-03-01 | Novartis Ag | New process for the preparation of intermediates useful for the manufacture nep inhibitors |
EP2522647A1 (en) | 2011-05-10 | 2012-11-14 | DSM IP Assets B.V. | Process of separating chiral isomers of chroman compounds and their derivatives and precursors |
EP2535323A1 (en) | 2011-06-14 | 2012-12-19 | DSM IP Assets B.V. | Hydrogenation of ketones having at least a carbon-carbon double bond in the gamma-,delta-position |
WO2014023848A1 (en) | 2012-08-10 | 2014-02-13 | Dsm Ip Assets B.V. | Protected tocopherol with reduced content of free tocopherol |
WO2014023849A1 (en) | 2012-08-10 | 2014-02-13 | Dsm Ip Assets B.V. | Tocopherols with increased color stability |
WO2014096096A1 (en) * | 2012-12-18 | 2014-06-26 | Dsm Ip Assets B.V. | Process of asymmetric hydrogenation of ketals and acetals |
WO2014097170A1 (en) | 2012-12-18 | 2014-06-26 | Dsm Ip Assets B.V. | Efficient process of asymmetric hydrogenation of unsturated ketones using additives |
WO2014096106A1 (en) * | 2012-12-18 | 2014-06-26 | Dsm Ip Assets B.V. | Using mixtures of e/z isomers to obtain quantitatively specific products by combined asymmetric hydrogenations |
WO2014096067A1 (en) * | 2012-12-18 | 2014-06-26 | Dsm Ip Assets B.V. | (6r,10r)-6,10,14-trimetylpentadecan-2-one prepared from (r)-6,10,14-trimetylpentadec-5-en-2-one |
WO2014096098A1 (en) * | 2012-12-18 | 2014-06-26 | Dsm Ip Assets B.V. | (6r,10r)-6,10,14-trimetylpentadecan-2-one prepared from 6,10,14-trimetylpentadeca-5,9,13-trien-2-one or 6,10,14-trimetylpentadeca-5,9-dien-2-one |
WO2014096107A1 (en) | 2012-12-18 | 2014-06-26 | Dsm Ip Assets B.V. | Using mixtures of e/z isomers to obtain quantitatively specific products by combining asymmetric hydrogenation and isomerization |
WO2014097173A1 (en) * | 2012-12-18 | 2014-06-26 | Dsm Ip Assets B.V. | (6r,10r)-6,10,14-trimetylpentadecan-2-one prepared from 6,10-dimetylundeca-3,5,9-trien-2-one |
WO2015001030A1 (en) | 2013-07-05 | 2015-01-08 | Dsm Ip Assets B.V. | Formation of chiral 4-chromanones using chiral pyrrolidines in the presence of ureas or thioureas |
WO2015001031A1 (en) | 2013-07-05 | 2015-01-08 | Dsm Ip Assets B.V. | Formation of chiral 4-chromanones using chiral pyrrolidines |
EP2842951A1 (en) | 2013-08-30 | 2015-03-04 | DSM IP Assets B.V. | Formation of chromanes and chromenes by using silver(I) or gold(I) salts or complexes |
WO2016188945A1 (en) | 2015-05-26 | 2016-12-01 | Dsm Ip Assets B.V. | Separation of chiral isomers by sfc |
WO2018108606A1 (en) * | 2016-12-12 | 2018-06-21 | Dsm Ip Assets B.V. | Process for the manufacture of 6,10-dimethylundecan-2-one, isophytol, alpha-tocopherol (acetate) and further intermediates thereof |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101565366B (en) * | 2008-04-25 | 2013-04-17 | 浙江九洲药业股份有限公司 | Application of iridium complex in asymmetry catalytic hydrogenation of unsaturated carboxylic acid |
MY171808A (en) * | 2012-12-18 | 2019-10-30 | Dsm Ip Assets Bv | (6r,10r)-6,10,14-trimetylpentadecan-2-one prepared from 3,7-dimetyloct-2-enal or 3,7-dimetylocta-2,6-dienal |
BR112015014335B1 (en) * | 2012-12-18 | 2020-12-08 | Dsm Ip Assets B.V. | (6r, 10r) -6,10,14-trimethylpentadecan-2-one prepared from 6,10-dimethylundec-5-en-2-one or 6.10 dimethylundeca-5,9-dien-2-one |
WO2014096066A1 (en) * | 2012-12-18 | 2014-06-26 | Dsm Ip Assets B.V. | (6r,10r)-6,10,14-trimetylpentadecan-2-one prepared from (r)-3,7-dimetyloct-6-enal |
KR20200038182A (en) * | 2018-10-02 | 2020-04-10 | 주식회사 글라세움 | Catalyst for asymmetric hydrogenation of compound having carbon double bond |
CN114790221A (en) * | 2022-05-25 | 2022-07-26 | 西安交通大学 | Synthesis and application of novel PCP pincerlike ligand based on indole skeleton |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0565975A2 (en) * | 1992-04-16 | 1993-10-20 | F. Hoffmann-La Roche Ag | Process for the preparation of isoprenoid derivatives |
US20010047110A1 (en) * | 1998-12-24 | 2001-11-29 | Takasago International Corporation | Method for producing axial asymmetric compounds, intermediates for producing the same, complexes of transition metals with novel axial asymmetric compounds as the ligands, catalysts for asymmetric hydrogenation, and catalysts for forming asymmetric carbon-carbon bonds |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63152337A (en) * | 1986-08-27 | 1988-06-24 | Takasago Corp | Production of optically active alcohol |
EP0258967B2 (en) * | 1986-08-27 | 1996-08-21 | Takasago Perfumery Co., Ltd. | Process for producing optically active alcohols |
DE3813624A1 (en) * | 1988-04-22 | 1989-11-02 | Basf Ag | METHOD FOR PRODUCING D- (ALPHA) -TOCOPHEROL FROM NATURAL PRE-PRODUCTS |
EP0398132B1 (en) | 1989-05-18 | 1995-09-20 | F. Hoffmann-La Roche Ag | Phosphorous compounds |
JPH0474192A (en) | 1990-07-12 | 1992-03-09 | Takasago Internatl Corp | 2,2'-bis(dicyclopentylphosphino)-1,1'-binaphthyl and transition metal complex comprising the same compound as ligand |
DE19619013A1 (en) | 1996-05-10 | 1997-11-13 | Basf Ag | Process for the preparation of hexahydrofarnesylacetone from 6,7-dihydro-geraniol and new intermediates for this process |
JPH10114767A (en) * | 1996-10-09 | 1998-05-06 | Sumitomo Chem Co Ltd | Production of tocopherol derivative |
JPH10251248A (en) | 1997-01-08 | 1998-09-22 | Sumitomo Chem Co Ltd | Production of coumarone derivative |
US6410755B1 (en) * | 1998-07-06 | 2002-06-25 | Dcv, Inc. | Method of vitamin production |
WO2000001685A1 (en) * | 1998-07-06 | 2000-01-13 | Eastman Chemical Company | Preparation of tocopherols |
ES2240297T3 (en) * | 2000-09-21 | 2005-10-16 | Solvias Ag | PHOSPHINITE-OXAZOLINES AND METAL COMPLEXES. |
DE10160142A1 (en) * | 2001-12-07 | 2003-06-18 | Basf Ag | Process for the preparation of tetrahydrogeraniol |
DE102004049631A1 (en) * | 2004-10-11 | 2006-04-20 | Basf Ag | Process for the preparation of optically active carbonyl compounds |
-
2005
- 2005-12-20 JP JP2007547315A patent/JP5090926B2/en active Active
- 2005-12-20 US US11/793,729 patent/US8426617B2/en active Active
- 2005-12-20 AT AT05820633T patent/ATE520678T1/en not_active IP Right Cessation
- 2005-12-20 WO PCT/EP2005/013694 patent/WO2006066863A1/en active Application Filing
- 2005-12-20 CN CN2005800445184A patent/CN101087774B/en active Active
- 2005-12-20 EP EP20050820633 patent/EP1828159B1/en active Active
- 2005-12-20 ES ES05820633T patent/ES2371653T3/en active Active
-
2007
- 2007-07-20 KR KR1020077016839A patent/KR101342722B1/en active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0565975A2 (en) * | 1992-04-16 | 1993-10-20 | F. Hoffmann-La Roche Ag | Process for the preparation of isoprenoid derivatives |
US20010047110A1 (en) * | 1998-12-24 | 2001-11-29 | Takasago International Corporation | Method for producing axial asymmetric compounds, intermediates for producing the same, complexes of transition metals with novel axial asymmetric compounds as the ligands, catalysts for asymmetric hydrogenation, and catalysts for forming asymmetric carbon-carbon bonds |
Non-Patent Citations (3)
Title |
---|
F. MENGES ET. AL.: "Threonine Derived Phosphinite-Oxazoline Ligands for the Ir-Catalysed Enantioselective Hydrogenation", ADVANCED SYNTHESIS AND CATALYSIS, vol. 344, no. 1, 2002, pages 40 - 44, XP009063294 * |
GUOPIN XU ET. AL.: "Asymmetric Hydrogenation of Aromatic Olefins Catalysed by Iridium Complexes of Proline Derived Phosphine-Oxazoline Ligands", TETRAHEDRON LETTERS, vol. 44, 2003, pages 963 - 965, XP002372463 * |
R.H. CRABTREE ET. AL.: "Directing Effects in Homogeneous Hydrogenation with [Ir(cod)(PCy3)(py)PF6", JOURNAL OF ORGANIC CHEMISTRY, vol. 51, 1986, pages 2655 - 2661, XP002372462 * |
Cited By (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2466629A (en) * | 2008-12-29 | 2010-06-30 | Schlumberger Holdings | Catalytic hydrogenation at a double bond with a transition metal complex of a heterocyclic nitrogenous organic base comprising a cyclic amidine group |
GB2466629B (en) * | 2008-12-29 | 2011-08-17 | Schlumberger Holdings | Catalytic hydrogenation |
US8242318B2 (en) | 2008-12-29 | 2012-08-14 | Schlumberger Technology Corporation | Catalytic hydrogenation |
WO2010125035A1 (en) * | 2009-04-30 | 2010-11-04 | Basf Se | Metal complex with low-coordinating counterion as polymerization catalyst for isobutes or an isobute-containing monomer composition |
WO2012025502A1 (en) | 2010-08-23 | 2012-03-01 | Novartis Ag | New process for the preparation of intermediates useful for the manufacture nep inhibitors |
EP2522647A1 (en) | 2011-05-10 | 2012-11-14 | DSM IP Assets B.V. | Process of separating chiral isomers of chroman compounds and their derivatives and precursors |
WO2012152779A1 (en) | 2011-05-10 | 2012-11-15 | Dsm Ip Assets B.V. | Process of separating chiral isomers of chroman compounds and their derivatives and precursors |
EP2535323A1 (en) | 2011-06-14 | 2012-12-19 | DSM IP Assets B.V. | Hydrogenation of ketones having at least a carbon-carbon double bond in the gamma-,delta-position |
WO2012171969A1 (en) | 2011-06-14 | 2012-12-20 | Dsm Ip Assets B.V. | HYDROGENATION OF KETONES HAVING AT LEAST A CARBON-CARBON DOUBLE BOND IN THE γ, δ-POSITION |
US9181163B2 (en) | 2011-06-14 | 2015-11-10 | Dsm Ip Assets B.V. | Hydrogenation of ketones having at least a carbon-carbon double bond in the γ,δ-position |
WO2014023848A1 (en) | 2012-08-10 | 2014-02-13 | Dsm Ip Assets B.V. | Protected tocopherol with reduced content of free tocopherol |
WO2014023849A1 (en) | 2012-08-10 | 2014-02-13 | Dsm Ip Assets B.V. | Tocopherols with increased color stability |
WO2014096107A1 (en) | 2012-12-18 | 2014-06-26 | Dsm Ip Assets B.V. | Using mixtures of e/z isomers to obtain quantitatively specific products by combining asymmetric hydrogenation and isomerization |
WO2014096096A1 (en) * | 2012-12-18 | 2014-06-26 | Dsm Ip Assets B.V. | Process of asymmetric hydrogenation of ketals and acetals |
WO2014096067A1 (en) * | 2012-12-18 | 2014-06-26 | Dsm Ip Assets B.V. | (6r,10r)-6,10,14-trimetylpentadecan-2-one prepared from (r)-6,10,14-trimetylpentadec-5-en-2-one |
WO2014096098A1 (en) * | 2012-12-18 | 2014-06-26 | Dsm Ip Assets B.V. | (6r,10r)-6,10,14-trimetylpentadecan-2-one prepared from 6,10,14-trimetylpentadeca-5,9,13-trien-2-one or 6,10,14-trimetylpentadeca-5,9-dien-2-one |
WO2014097170A1 (en) | 2012-12-18 | 2014-06-26 | Dsm Ip Assets B.V. | Efficient process of asymmetric hydrogenation of unsturated ketones using additives |
WO2014097173A1 (en) * | 2012-12-18 | 2014-06-26 | Dsm Ip Assets B.V. | (6r,10r)-6,10,14-trimetylpentadecan-2-one prepared from 6,10-dimetylundeca-3,5,9-trien-2-one |
WO2014096106A1 (en) * | 2012-12-18 | 2014-06-26 | Dsm Ip Assets B.V. | Using mixtures of e/z isomers to obtain quantitatively specific products by combined asymmetric hydrogenations |
EA033302B9 (en) * | 2012-12-18 | 2020-01-22 | ДСМ АйПи АССЕТС Б.В. | (6r,10r)-6,10,14-trimetylpentadecan-2-one prepared from 6,10,14-trimetylpentadeca-5,9,13-trien-2-one or 6,10,14-trimetylpentadeca-5,9-dien-2-one |
EA033451B1 (en) * | 2012-12-18 | 2019-10-31 | Dsm Ip Assets Bv | Process of asymmetric hydrogenation of ketals and acetals |
US10047019B2 (en) | 2012-12-18 | 2018-08-14 | Dsm Ip Assets B.V. | Efficient process of asymmetric hydrogenation of unsaturated ketones using additives |
US9458076B2 (en) | 2012-12-18 | 2016-10-04 | Dsm Ip Assets B.V. | Using mixtures of E/Z isomers to obtain quantitatively specific products by combined asymmetric hydrogenations |
EA033435B1 (en) * | 2012-12-18 | 2019-10-31 | Dsm Ip Assets Bv | Using mixtures of e/z isomers to obtain quantitatively specific products by combining asymmetric hydrogenation and isomerization |
US9561989B2 (en) | 2012-12-18 | 2017-02-07 | Dsm Ip Assets B.V. | Process of asymmetric hydrogenation of ketals and acetals |
US9573872B2 (en) | 2012-12-18 | 2017-02-21 | Dsm Ip Assets B.V. | Using mixtures of E/Z isomers to obtain quantitatively specific products by combining asymmetric hydrogenation and isomerization |
US9611200B2 (en) | 2012-12-18 | 2017-04-04 | Dsm Ip Assets B.V. | (6R,10R)-6,10,14-trimetylpentadecan-2-one prepared from 6,10,14 trimetylpentadeca-5,9,13-trien-2-one or 6,10,14-trimetylpentadeca-5,9-dien-2-one |
EA028168B1 (en) * | 2012-12-18 | 2017-10-31 | ДСМ АйПи АССЕТС Б.В. | Efficient process of asymmetric hydrogenation of unsaturated ketones and aldehydes using additives |
EA029733B1 (en) * | 2012-12-18 | 2018-05-31 | ДСМ АйПи АССЕТС Б.В. | Using mixtures of e/z isomers to obtain quantitatively specific products by combined asymmetric hydrogenations |
EA033302B1 (en) * | 2012-12-18 | 2019-09-30 | ДСМ АйПи АССЕТС Б.В. | (6r,10r)-6,10,14-trimetylpentadecan-2-one prepared from 6,10,14-trimetylpentadeca-5,9,13-trien-2-one or 6,10,14-trimetylpentadeca-5,9-dien-2-one |
WO2015001030A1 (en) | 2013-07-05 | 2015-01-08 | Dsm Ip Assets B.V. | Formation of chiral 4-chromanones using chiral pyrrolidines in the presence of ureas or thioureas |
WO2015001031A1 (en) | 2013-07-05 | 2015-01-08 | Dsm Ip Assets B.V. | Formation of chiral 4-chromanones using chiral pyrrolidines |
EP2842951A1 (en) | 2013-08-30 | 2015-03-04 | DSM IP Assets B.V. | Formation of chromanes and chromenes by using silver(I) or gold(I) salts or complexes |
WO2016188945A1 (en) | 2015-05-26 | 2016-12-01 | Dsm Ip Assets B.V. | Separation of chiral isomers by sfc |
WO2018108606A1 (en) * | 2016-12-12 | 2018-06-21 | Dsm Ip Assets B.V. | Process for the manufacture of 6,10-dimethylundecan-2-one, isophytol, alpha-tocopherol (acetate) and further intermediates thereof |
Also Published As
Publication number | Publication date |
---|---|
US8426617B2 (en) | 2013-04-23 |
KR101342722B1 (en) | 2013-12-19 |
ATE520678T1 (en) | 2011-09-15 |
JP5090926B2 (en) | 2012-12-05 |
EP1828159A1 (en) | 2007-09-05 |
EP1828159B1 (en) | 2011-08-17 |
ES2371653T3 (en) | 2012-01-05 |
JP2008524288A (en) | 2008-07-10 |
CN101087774A (en) | 2007-12-12 |
KR20070089874A (en) | 2007-09-03 |
US20080039638A1 (en) | 2008-02-14 |
CN101087774B (en) | 2012-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1828159B1 (en) | Asymmetric hydrogenation of alkenes using chiral iridium complexes | |
EP2720996B1 (en) | HYDROGENATION OF KETONES HAVING AT LEAST A CARBON-CARBON DOUBLE BOND IN THE gamma,delta-POSITION | |
JP6481171B2 (en) | (6R, 10R) -6,10,14-trimethylpentadecane prepared from 6,10-dimethylundec-5-en-2-one or 6,10-dimethylundec-5,9-dien-2-one -2-one | |
JP6390048B2 (en) | Use of a mixture of E / Z isomers to obtain specific products quantitatively by combined asymmetric hydrogenation | |
JP6582324B2 (en) | Prepared from 6,10,14-trimethylpentadeca-5,9,13-trien-2-one or 6,10,14-trimethylpentadeca-5,9-dien-2-one (6R, 10R)- 6,10,14-trimethylpentadecan-2-one | |
WO2005035490A2 (en) | PROCESS FOR SYNTHESIZING d-TOCOTRIENOLS | |
EP3039017B1 (en) | Formation of chromanes and chromenes by using silver(i) or gold(i) salts or complexes | |
JP6476496B2 (en) | Method for asymmetric hydrogenation of ketals and acetals | |
EP2935191B1 (en) | Preparation of (6r,10r)-6,10,14-trimetylpentadecan-2-one from 3,7-dimetyloct-2-enal or 3,7-dimetylocta-2,6-dienal | |
JPH02292277A (en) | Preparation of vinylchroman | |
FI78289B (en) | FOERFARANDE FOER FRAMSTAELLNING AV TERAPEUTISKT ANVAENDBARA BICYKLO / 3.2.0 / HEPTAN-6-ONOXIMETERDERIVAT. | |
EP2935190A1 (en) | (6r,10r)-6,10,14-trimetylpentadecan-2-one prepared from 6,10-dimetylundeca-3,5,9-trien-2-one | |
EP2935176B1 (en) | (6r,10r)-6,10,14-trimetylpentadecan-2-one prepared from (r)-3,7-dimetyloct-6-enal | |
Deutsch | Lewis Acid Promoted Ene Reactions of Alpha, Beta-unsaturated Carbonyl Compounds and Synthesis of the Hexahydronaphthalene Moieties of Compactin and Mevinolin | |
WO2004108652A2 (en) | Enantioselective process for the preparation of methyl dihydroepijasmonate | |
EP2935175A1 (en) | (6r,10r)-6,10,14-trimetylpentadecan-2-one prepared from (r)-6,10,14-trimetylpentadec-5-en-2-one |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005820633 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007547315 Country of ref document: JP Ref document number: 200580044518.4 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 5205/DELNP/2007 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077016839 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11793729 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2005820633 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11793729 Country of ref document: US |